Emily Alpert

Ms. Emily Alpert

Rutgers, The State University of New Jersey, Newark, New Jersey, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
FAFavour Akinjiyan
Favour Akinjiyan
RDRitu Dave
Ritu Dave
EAEmily Alpert
Emily Alpert
GLGregory D. Longmore
Gregory D. Longmore
KFKatherine Fuh
Katherine Fuh
Ovarian cancer has the highest mortality of all gynecologic malignancies. As such, there is a need to identify molecular mechanisms that underlie tumor metastasis in ovarian cancer. Increased expression of receptor tyrosine kinase, DDR2, has been associated with worse patient survival. Identifying downstream targets of DDR2 may allow specific modulation of ovarian cancer metastatic pathways. Additionally, stromal cells play a critical role in metastasis. The crosstalk between tumor and stromal cells can lead to tumor progression. We first identified that tumor cells co-cultured with DDR2-expressing fibroblasts had lower periostin expression when compared to tumor cells co-cultured with DDR2-depleted fibroblasts. We confirmed that DDR2 regulates POSTN expression in ovarian cancer-associated fibroblasts (CAFs). We found that mesothelial cell clearance and invasion by tumor cells were enhanced three-fold when DDR2 and POSTN-expressing CAFs were present compared to DDR2 and POSTN-depleted CAFs. Furthermore, DDR2-depleted and POSTN-overexpressing CAFs co-injected with ovarian tumor cells had increased tumor burden compared to mice injected with tumor cells and DDR2 and POSTN-depleted CAFs. Furthermore, we demonstrated that DDR2 regulates periostin expression through integrin B1 (ITGB1). Stromal DDR2 is highly correlated with stromal POSTN expression in ovarian cancer patient tumors. Thus, DDR2 expression in CAFs regulates the steps of ovarian cancer metastasis through periostin.

Verified
Journal Article
Open access
PDF file
YAYasmin Abedin
Yasmin Abedin
SGSofia D Gabrilovich
Sofia D Gabrilovich
EAEmily Alpert
Emily Alpert
ERErica Rego
Erica Rego
SBSalma Begum
Salma Begum
NDNataki Douglas
Nataki Douglas
Uterine leiomyosarcoma (uLMS) is a rare and aggressive cancer with few effective therapeutics. The Notch signaling pathway is evolutionarily conserved with oncogenic properties, but it has not been well studied in uLMS. The purpose of our study was to determine expression of Notch family genes and proteins and to investigate the therapeutic effect of γ-secretase inhibitors (GSIs), indirect inhibitors of Notch signaling, in uLMS. We determined expression of Notch genes and proteins in benign uterine smooth muscle tissue, fibroids, and uLMS samples by immunostaining and in two uLMS cell lines, SK-UT-1B (uterine primary) and SK-LMS-1 (vulvar metastasis) by RT-PCR, Western blot and immunostaining. We exposed our cell lines to GSIs, DAPT and MK-0752, and measured expression of HES1, a downstream effector of Notch. Notch proteins were differentially expressed in uLMS. Expression of NOTCH3 and NOTCH4 was higher in uLMS samples than in benign uterine smooth muscle and fibroids. Expression of NOTCH4 was higher in SK-LMS-1 compared to SK-UT-1B. Exposure of SK-UT-1B and SK-LMS-1 to DAPT and MK-0752 decreased expression of HES1 and decreased uLMS cell viability in a dose- and time-dependent manner that was unique to each GSI. Our findings suggest that GSIs are potential therapeutics for uLMS, albeit with limited efficacy.

10 June 2024 in Cancers
Verified
Journal Article
Open access
PDF file
YAYasmin Abedin
Yasmin Abedin
AFAlexander Fife
Alexander Fife
CSCherie-Ann Samuels
Cherie-Ann Samuels
RWRasheena Wright
Rasheena Wright
TMTrystn Murphy
Trystn Murphy
NDNataki Douglas
Nataki Douglas
Due to limited effective therapeutics for uterine leiomyosarcoma (uLMS), the impact of the gamma secretase inhibitor (GSI) MK-0752 with common chemotherapeutics was explored in uLMS. MTT assays were performed on two human uLMS cell lines, SK-UT-1B and SK-LMS-1, using MK-0752, docetaxel, doxorubicin, and gemcitabine, individually and in combination, to determine cell viability after treatment. Synergistic combinations were used in transwell invasion assays, cell cycle flow cytometry, proliferation assays, and RNA sequencing. In SK-UT-1B, MK-0752 was synergistic with doxorubicin and gemcitabine plus docetaxel. In SK-LMS-1, MK-0752 was synergistic with all individual agents and with the combination of gemcitabine plus docetaxel. MK-0752, gemcitabine, and docetaxel decreased invasion in SK-UT-1B 2.1-fold* and in SK-LMS-1 1.7-fold*. In SK-LMS-1, invasion decreased 1.2-fold* after treatment with MK-0752 and docetaxel and 2.2-fold* after treatment with MK-0752 and doxorubicin. Cell cycle analysis demonstrated increases in the apoptotic sub-G1 population with MK-0752 alone in SK-UT-1B (1.4-fold*) and SK-LMS-1 (2.7-fold**), along with increases with all combinations in both cell lines. The combination treatments had limited effects on proliferation, while MK-0752 alone decreased proliferation in SK-LMS-1 (0.63-fold**). Both MK-0752 alone and in combination altered gene expression and KEGG pathways. In conclusion, the combinations of MK-0752 with either doxorubicin, docetaxel, or gemcitabine plus docetaxel are potential novel therapeutic approaches for uLMS. (* p < 0.05, ** p < 0.01).

30 October 2024 in Academic Pediatrics
Verified
Journal Article
Closed access
EAEmily Alpert
Emily Alpert
JWJoanne N. Wood
Joanne N. Wood
JSJustine Shults
Justine Shults
DLDaniel M. Lindberg
Daniel M. Lindberg
KCKristine A. Campbell
Kristine A. Campbell
MHM. Katherine Henry
M. Katherine Henry

17 August 2026 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
EAEmily Alpert
Emily Alpert
Jacqueline Kent-MarvickJacqueline Kent-Marvick
Jacqueline Kent-Marvick
OCOmaris Caceres
Omaris Caceres
APAidan Perner
Aidan Perner
FMFlorence M. Momplaisir
Florence M. Momplaisir
SKShimrit Keddem
Shimrit Keddem
Introduction: Nineteen percent of new HIV diagnoses in the United States in 2022 occurred in women. One barrier to HIV prevention is low perception of possibility of infection. We explored the qualitative data on perception of chances of HIV infection in women to elucidate how women conceive potential for infection. Methods: Included articles were published between 2014 and 2024 with information on women, HIV, and perception of potential for infection. The codebook was created from emerging and theoretical constructs. Articles were coded using Dedoose. Codes were reviewed for cross-cutting themes and summaries created. Confidence in review findings was assessed with the CERQual approach. Results: The meta-synthesis included twenty papers. These included four papers focused on women engaged in substance use and five focused on Black individuals. Four themes emerged: women controlled aspects of their lives and altered possible exposures with the use of condoms or needle exchange programs, women knew they could not control all their potential exposures, misinformation and incomplete information affected women’s ability to assess their exposures, and perceptions of potential for infection were dynamic and dependent on current priorities in their lives. Conclusions: Women assessed their possibility for HIV based on their perception of control, their access to information, and based on life circumstances. Understanding how women think about their potential for infection can allow healthcare professionals to better counsel women on their chances of HIV transmission, leading to greater HIV prevention.